Overview

AZD6765 for Treatment Resistant Depression

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Criteria
Inclusion Criteria:

- Diagnosis of Depression

- Inadequate response to an adequate course of antidepressants

Exclusion Criteria:

- Psychiatric disorder other than depression

- Pregnancy or lactation

- Current diagnosis of cancer